Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma

被引：14
|
作者：
Kim, Jung Guk [1 ]
机构：
[1] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, 680 Gukchaebosang Ro, Daegu 700842, South Korea
来源：
ENDOCRINOLOGY AND METABOLISM | 2014年 / 29卷 / 03期
关键词：
Thyroid neoplasms; Targeted therapies;
D O I：
10.3803/EnM.2014.29.3.211
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Four proto-oncogenes commonly associated with well-differentiated thyroid carcinoma, rearranged during transfection (RET)/papillary thyroid cancer, BRAF, RAS, and PAX8/peroxisome proliferator activated receptor-., may carry diagnostic and prognostic significance. These oncogenes can be used to improve the diagnosis and management of well-differentiated thyroid carcinoma. Limited therapeutic options are available for patients with metastatic well-differentiated thyroid cancer, necessitating the development of novel therapies. Vascular endothelial growth factor (VEGF)-and RET-directed therapies such as sorafenib, motesanib, and sunitinib have been shown to be the most effective at inducing clinical responses and stabilizing the disease process. Further clinical trials of these therapeutic agents may soon change the management of thyroid cancer.
引用
收藏
页码：211 / 216
页数：6
相关论文
共 50 条
  • [21] THE SURGICAL-TREATMENT OF WELL-DIFFERENTIATED CARCINOMA OF THE THYROID
    ONTAI, S
    STRAEHLEY, CJ
    AMERICAN SURGEON, 1985, 51 (11) : 653 - 657
  • [22] American Thyroid Association guidelines for the management of well-differentiated thyroid carcinoma
    Wallwork, Benjamin
    ANZ JOURNAL OF SURGERY, 2019, 89 (1-2) : 9 - 9
  • [23] Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
    Vijayvergia, Namrata
    Dasari, Arvind
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (12)
  • [24] Targeted Therapies in the Management of Well-Differentiated Digestive and Lung Neuroendocrine Neoplasms
    Namrata Vijayvergia
    Arvind Dasari
    Current Treatment Options in Oncology, 2020, 21
  • [25] Targeted molecular therapies in thyroid carcinoma
    Romagnoli, Serena
    Moretti, Sonia
    Voce, Pasquale
    Puxeddu, Efisio
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2009, 53 (09) : 1061 - 1073
  • [26] Molecular diagnostic methods in the diagnosis and follow-up of well-differentiated thyroid carcinoma
    Rodrigo, Juan Pablo
    Rinaldo, Alessandra
    Devaney, Kenneth O.
    Shaha, Ashok R.
    Ferlito, Alfio
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2006, 28 (11): : 1032 - 1039
  • [27] The role of operations for distantly metastatic well-differentiated thyroid carcinoma
    Stojadinovic, A
    Shoup, M
    Ghossein, RA
    Nissan, A
    Brennan, MF
    Shah, JP
    Shaha, AR
    SURGERY, 2002, 131 (06) : 636 - 643
  • [28] MANAGEMENT OF LOCAL RECURRENCE IN WELL-DIFFERENTIATED THYROID-CARCINOMA
    HAMBY, LS
    MCGRATH, PC
    SCHWARTZ, RW
    SLOAN, DA
    SIMPSON, WG
    KENADY, DE
    JOURNAL OF SURGICAL RESEARCH, 1992, 52 (02) : 113 - 117
  • [29] Regional Metastases in Well-Differentiated Thyroid Carcinoma: Pattern of Spread
    Yanir, Yoav
    Doweck, Ilana
    LARYNGOSCOPE, 2008, 118 (03): : 433 - 436
  • [30] Implication of BRAF mutations in well-differentiated thyroid carcinoma.
    Dominguez Rullan, J. A.
    Hernanz Lucas, R.
    Vallejo Ocana, C.
    Martin Martin, M.
    Sancho Garcia, S.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S443 - S443
12345